73% say it causes care disruptions—easier access and clearer guidance could help protect patient loyalty.

Pharma is still interested in China-developed drugs amid US scrutiny and competition.

The agency’s view on overall impressions is reaching beyond medical claims, which can lead to costly reworking or removal of creative for pharma brands.

The rebrand from Novo Nordisk to Novo supports its culture reset, but its pipeline and commercial progress matter far more.

Rising FDA enforcement is reshaping pharma advertising. This report looks at how enforcement changes will affect creative, claims, and media channels, and what marketers can do to mitigate regulatory risk.

New, affordable GLP-1 access for Medicare beneficiaries creates an opening for marketers to address seniors’ specific weight loss needs.

As employer health costs climb, reduced coverage for weight loss drugs will expand the self-pay GLP-1 market and intensify price competition among drugmakers.

Drug price negotiations helped lower overall prices, but many patients still don't feel savings at the counter.

Novo Nordisk adds AWS to its AI roster. Deep-pocketed drugmakers can test multiple AI partners, an advantage smaller rivals may lack.

Novo's Wegovy pill gains failed to offset declines in injectable sales. Investors continue to favor companies like Lilly with broader drug pipelines despite a positive outlook for GLP-1 pills.

GLP-1s are creating a new consumer economy that reaches beyond healthcare. As treatment becomes easier to access, brands must balance growth opportunities with misinformation, fragmented support, and rising expectations for lifestyle services.

An experimental heart drug missed a key clinical trial result, delivering a blow to Novo Nordisk as it looks to expand beyond GLP-1s.

Novo's GLP-1 ad lawsuit against Lilly could redefine the standards for comparative drug advertising in a market projected to reach $200 billion.

Wegovy pill's lead over Foundayo signals drug marketers need to build consumer and healthcare provider brand awareness before launch.

Medicare weight loss drug program will lower prescription costs for many older adults, but eligibility and prior approvals may leave patients relying on providers and pharmacies for answers.

AI visibility for pharma brands won't replace physician outreach or advertising, but it reinforces credibility.

They must clearly distinguish their products from gray-market manufacturers caught in the FDA’s crosshairs.

Novo Nordisk’s oral obesity treatment is set for a private-pay debut in the UK as drugmakers look to broaden GLP-1 adoption beyond injections.

But competitor data shows obesity care may widen beyond two leaders and favor whoever deliv

Pharma companies back rapid reviews to speed patient access, while opponents are concerned about transparency lapses and safety trade-offs.